{
    "nct_id": "NCT04063527",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2019-08-21",
    "study_start_date": "2012-07-20",
    "study_completion_date": null,
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: adjuvant chemotherapy"
            }
        ]
    },
    "long_title": "Randomized Phase III Trial of the Need for Adjuvant Chemotherapy in Stage I Epithelial Ovarian Cancer After Comprehensive Staging Surgery",
    "last_updated": "2019-08-30",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE3",
    "principal_investigator": "NA",
    "principal_investigator_institution": "Japanese Gynecologic Oncology Group",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 360,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "1. Patients with a diagnosis of histopathologically epithelial ovarian cancer",
        "2. FIGO Stages Ia(Grade2/3, clear cell carcinoma), Ib(Grade2/3, clear cell carcinoma) and Ic(b)(all degree of differentiation and all histologic type)",
        "3. Patients with a diagnosis of advanced stage by comprehensive staging or restaging laparotomy.",
        "4. Patients who received comprehensive staging surgery (basic surgical techniques (total hysterectomy, bilateral salpingo-oophorectomy, and omentectomy) as well as peritoneal cytology, multiple biopsies of the peritoneum (\\[Peritoneal biopsy\\] see details below), retroperitoneal lymph node dissection (see details below \\[Retroperitoneal lymph node dissection\\]).",
        "However, for the following cases, it is eligible as a condition to record on the official document.",
        "* Peritoneal biopsy: peritoneal metastasis is not recognized by macroscopic and palpation in the stipulated site, and the case that biopsy has not been performed.",
        "* Retroperitoneal lymph node dissection: the case that lymph nodes of the stipulated range has been dissected however the prescribed number has not been reached.",
        "5. Age: 20 or older",
        "6. Performance status (PS):0-1",
        "7. Case with initial therapy for postoperative primary lesion",
        "8. Patient possible to receive the first study treatment within 8 weeks after the comprehensive staging surgery",
        "9. Reasonable organ function",
        "10. Patient must have signed informed consent.",
        "Exclude - Exclusion Criteria:",
        "Exclude - 1. FIGO Stages Ic(a), Ic(1) and Ic(2)",
        "Exclude - 2. Patients containing sarcoma elements",
        "Exclude - 3. Patients with any signs of interstitial pneumonia or pulmonary fibrosis by chest radiography and CT",
        "Exclude - 4. Patients with serious complications",
        "Exclude - 5. Patients with active infection",
        "Exclude - 6. Patients with intestinal paralysis or intestinal obstruction",
        "Exclude - 7. Patients who have a synchronous malignancy or who have been progression-free less than 5 years for a metachronous malignancy",
        "Exclude - 8. Patients with previous chemotherapy or radiation therapy",
        "Exclude - 9. Patients with serious drug hypersensitivity",
        "Exclude - 10. Patients with peripheral motor/sensory neuropathy \\[grade2,3,4 Common Terminology Criteria for Adverse Events (CTCAE) 4.0\\]",
        "Exclude - 11. Patients who have had a hypersensitivity reaction to polyoxyethylated or hydrogenated castor oil",
        "Exclude - 12. Patients with positive HBsAg. Patients with more than 2.1 log/copies ml based on fixed Hepatitis B virus (HBV)-DNA who are positive with either antigen-positive Hepatitis B (HBs), anti-hepatitis B core antigen or anti-hepatitis B surface antigen.",
        "Exclude - 13. Patients who are inappropriate to enter this study with any safety reasons, judged by the treating physician"
    ],
    "short_title": "Phase III Trial of Stage I Ovarian Cancer After Surgery",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Japanese Gynecologic Oncology Group",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "To compare the Overall survival of adjuvant chemotherapy versus observation in stage I epithelial ovarian cancer after comprehensive staging surgery",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "Standard therapy",
                        "arm_internal_id": 0,
                        "arm_description": "combination of paclitaxel and carboplatin",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: adjuvant chemotherapy",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Observation",
                        "arm_internal_id": 1,
                        "arm_description": "Observation",
                        "arm_suspended": "N",
                        "dose_level": []
                    }
                ],
                "match": [
                    {
                        "clinical": {
                            "age_numerical": ">=20",
                            "gender": "Female",
                            "disease_status": [
                                "Early Stage",
                                "Advanced"
                            ],
                            "oncotree_primary_diagnosis": "Ovarian Epithelial Tumor"
                        }
                    }
                ]
            }
        ]
    }
}